Aegerion Pharmaceuticals (AEGR) Announces Date of Advisory Committee Review for Lomitapide NDA

Article Stock Quotes (1) Comments (0)

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee on October 17, 2012, to review the Company's New Drug Application for lomitapide in the treatment of adult patients with Homozygous Familial Hypercholesterolemia (HoFH).

Aegerion is seeking authorization to market lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with HoFH.

The Endocrinologic and Metabolic Drugs Advisory Committee is an independent panel of experts that reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of endocrine and metabolic disorders, and makes appropriate recommendations to the FDA.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Aegerion (AEGR) Pops on Juxtapid Price Increase; Leerink Boosts PT to $65
• Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
• XenoPort (XNPT) Arbaclofen Placarbil Phase 3 Misses Endpoints

Create E-mail Alert Related Categories

FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?